JSPR (Jasper Therapeutics) 3-Year RORE % : -16.84% (As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
29 GF Score
Price $0.58
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics 3-Year RORE %?

Jasper Therapeutics JSPR -1.49% 29 3-Year RORE % is -16.84 as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,289 Biotechnology companies, Jasper Therapeutics ranks worse than 55.47% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Jasper Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -16.84%.

The industry rank for Jasper Therapeutics's 3-Year RORE % or its related term are showing as below:

JSPR's 3-Year RORE % is ranked worse than
55.47% of 1289 companies
in the Biotechnology industry
Industry Median: -11.44 vs JSPR: -16.84

Jasper Therapeutics  (NAS:JSPR) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Jasper Therapeutics 3-Year RORE % Related Terms


Jasper Therapeutics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics 3-Year RORE % Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 -25.85 -25.48 -10.16

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.44 -18.48 -12.63 -10.16 -16.84

JSPR vs CVKD, BRTX, APRE: 3-Year RORE % Comparison

For the Biotechnology subindustry, Jasper Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's 3-Year RORE % falls into.


JSPR
29GF Score
Jasper Therapeutics Inc JSPR
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics 3-Year RORE % Calculation

Jasper Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -3.23--5.6 )/( -14.07-0 )
=2.37/-14.07
=-16.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -16.84 mean?
Jasper Therapeutics (JSPR) has a 3-Year RORE % of -16.84 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Jasper Therapeutics and its competitors. According to the industry distribution chart, Jasper Therapeutics ranks #715 out of 1289 companies in the Biotechnology industry, placing it in the top 55.5%.
Is Jasper Therapeutics' 3-Year RORE % too high?
Jasper Therapeutics' current 3-Year RORE % is -16.84. Based on the distribution chart, Jasper Therapeutics ranks #715 out of 1289 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jasper Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' 3-Year RORE % compare to CVKD and BRTX?
According to the Biotechnology industry distribution chart, Jasper Therapeutics ranks #715 out of 1289 companies for 3-Year RORE %. This places Jasper Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Jasper Therapeutics and its competitors. Jasper Therapeutics's current 3-Year RORE % is -16.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current 3-Year RORE % of -16.84. The current 3-Year RORE % is -16.84. Jasper Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current 3-Year RORE % is -16.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
29GF Score

Get the complete analysis for JSPR

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price